My research is focused on the development and clinical translation of novel therapies for acute leukemias. I currently lead multiple clinical trials at the Dana Farber Harvard Cancer Center for patients with advanced leukemia and hematologic malignancies. I have a specific interest in studying FLT3 inhibition, aurora kinase inhibition, and antibody-drug conjugates as novel therapies.
Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez H, Matulis CR, Edmonds KM, Iafrate AJ, Straley K, Yen K, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood, 2012;120(23):4649-52.
Fathi AT, Le L, Hasserjian RP, Sadrzadeh H, Levis M, Chen YB. FLT3 inhibitor-induced neutrophilic dermatosis. Blood, 2013;122(2):239-42.
Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT. Trends in all-cause mortality among patients with CML: A SEER database analysis. Cancer, 2013;119(14):2620-9.
Fathi AT, Chabner BA. FLT3 inhibition as therapy: A record of trials and tribulations. Oncologist, 2011;16(8):1162-74.
Call the Massachusetts General Hospital physician referral service at 800-711-4644.
Mass General accepts most health insurance plans. Find out what you need to know before coming to Mass General.
Driving to Mass General? Get driving directions or locate a parking lot on the hospital's main campus.